Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Terminated
Leading BioSciences, Inc
Phase 2
Septic shock is a potentially life-threatening condition that can result in multi-organ
dysfunction syndrome (MODS) and mortality. LB1148 was formulated to preserve gut integrity
during physiological shock and ameliorate the subsequent autodigestion leading to MODS and
mortality. The purpose of this study in septic shock patients is to determine if enteral
administration of LB1148 will increase the number of days alive without cardiovascular,
pulmonary or renal replacement therapy through Day 28.
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
Recruiting
Leading BioSciences, Inc
Phase 2
The purpose of this study is to establish preliminary evidence of the efficacy, safety, and
tolerability of LB1148 for the treatment of post-operative ileus and intra-abdominal
adhesions in subjects undergoing elective bowel resection.
A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection
Completed
Ronald Hurst, MD, FACS
Phase 1
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of
LB1148 in subjects undergoing elective bowel resection. During abdominal surgery, surgeons
handle, manipulate, and often make incisions in the bowel. These actions can create bruising,
lesions, and microscopic damage to the bowel, which may allow digestive enzymes to cross the
intestinal mucosal barrier potentially resulting in injury both locally and remotely. Leaking
digestive enzymes may delay return of normal gastrointestinal (GI) function, lead to a lack
of motility in the intestine (ileus), and promote the formation of intestinal scar tissue
(adhesions).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
